EHC 2024 Archives - Medical Conferences

Home > Neurology > EHC 2024

Read the full Report (pdf)

European Headache Federation
04–07 December 2024
Rotterdam, the Netherlands

More education on migraine features is needed

Presented By

Dr Lucas Overeem, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:37

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments

Presented By

Ms Deirdre Boucherie, Erasmus University Medical Centre Rotterdam, the Netherlands

Conference

EHC 2024

Type

News article

6 January 2025 11:08

Online First

Understanding Migraine Mechanisms

The locus coeruleus is involved in processing pain in migraine

Presented By

Dr Veronica Munday, King’s College London, UK

Conference

EHC 2024

Type

News article

6 January 2025 11:47

Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura

Presented By

Ms Zi-Rou Jiang, National Yang Ming Chiao Tung University, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:46

Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome

Presented By

Dr Yu-Hsiang Ling, Taipei General Veterans Hospital, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:44

Diagnostic and Predictive Tools

AI can enhance migraine diagnosis using easy-to-measure clinical data

Presented By

Dr Antonios Danelakis, Norwegian University of Science and Technology, Norway

Conference

EHC 2024

Type

News article

6 January 2025 11:43

New tool adequately captures multiple pain types in trigeminal neuralgia

Presented By

Dr Amine Tahiri, Noema Pharma, Switzerland

Trial

NOE-PRO-201

Conference

EHC 2024

Type

News article

6 January 2025 11:41

MRI analyses suggest that migraine is not associated with altered brain white matter

Presented By

Dr Cédric Gollion, University Hospital Centre of Toulouse, France

Trial

REFORM

Conference

EHC 2024

Type

News article

6 January 2025 11:39

More education on migraine features is needed

Presented By

Dr Lucas Overeem, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:37

Treatment Innovations

PACAP-targeting therapies: a future option for migraine?

Presented By

Dr Zixuan Alice Zhuang, University of Copenhagen, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:36

Rapid complete responses with atogepant

Presented By

Dr Andreas Gantenbein, Zurzach Care, Switzerland

Trial

Phase 3, ADVANCE, ELEVATE, PROGRESS

Conference

EHC 2024

Type

News article

6 January 2025 11:35

Cabergoline is a potential add-on treatment option in patients with migraine

Presented By

Dr Astrid Hjelholt, Aarhus University Hospital, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:32

Nitroglycerin-induced migraine targetable by different agents

Presented By

Dr Charlotte Ernstsen Lauritzen, H. Lundbeck A/S, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:31

Rimegepant reduces migraine symptoms through 1 year of treatment

Presented By

Dr Shengyuan Yu, PLA General Hospital, China

Trial

Phase 2

Conference

EHC 2024

Type

News article

6 January 2025 11:29

Fremanezumab is a treatment option for paediatric patients with episodic migraine

Presented By

Prof. Patricia Pozo-Rosich, Vall d’Hebron Institute of Research, Spain

Trial

Phase 3, SPACE-EM

Conference

EHC 2024

Type

News article

6 January 2025 11:27

What brain changes are associated with fremanezumab treatment success?

Presented By

Prof. Ángel Guerrero, University of Valladolid, Spain

Trial

FreMRI

Conference

EHC 2024

Type

News article

6 January 2025 11:25

Preventative Therapies in Real-world Context

Low discontinuation rates with preventative galcanezumab in a real-world setting

Presented By

Dr Sait Ashina, Harvard Medical School, MA, USA

Trial

TRIUMPH

Conference

EHC 2024

Type

News article

6 January 2025 11:23

Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders

Presented By

Dr Mantas Jokubaitis, King’s College London, UK

Conference

EHC 2024

Type

News article

6 January 2025 11:21

Biofeedback training can reduce affected days in episodic migraine

Presented By

Dr Amalie Christine Poole, Norwegian University of Science and Technology, Norway

Trial

BioCer

Conference

EHC 2024

Type

News article

6 January 2025 11:20

Virtual reality interventions can reduce pain perception of chronic headache

Presented By

Prof. Sara Bottiroli, University of Pavia, Pavia, Italy

Conference

EHC 2024

Type

News article

6 January 2025 11:18

Risk Factors and Long-term Management

Can predisposing factors be targeted to reduce new migraine incidence?

Presented By

Ms Maria Terhart, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:15

Active migraine comes at a high cost in Spain

Presented By

Dr Margarita Sánchez del Río, Clinica Universidad de Navarra, Spain

Conference

EHC 2024

Type

News article

6 January 2025 11:13

Many patients, including non-responders, prefer triptans over non-headache-specific medication

Presented By

Dr Arne Hostens, Free University of Brussels, Belgium

Conference

EHC 2024

Type

News article

6 January 2025 11:12

Systemic Conditions and Migraine

DPP-4 is better target to lower migraine rates in patients with type 2 diabetes

Presented By

Dr Chen Ting-Chuan, Taichung Veterans General Hospital, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:10

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments

Presented By

Ms Deirdre Boucherie, Erasmus University Medical Centre Rotterdam, the Netherlands

Conference

EHC 2024

Type

News article

6 January 2025 11:08

Medical Conferences

EHC 2024

Featured articles

More education on migraine features is needed

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments

CONTENTS

Online First

Understanding Migraine Mechanisms

The locus coeruleus is involved in processing pain in migraine

Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura

Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome

Diagnostic and Predictive Tools

AI can enhance migraine diagnosis using easy-to-measure clinical data

New tool adequately captures multiple pain types in trigeminal neuralgia

MRI analyses suggest that migraine is not associated with altered brain white matter

More education on migraine features is needed

Treatment Innovations

PACAP-targeting therapies: a future option for migraine?

Rapid complete responses with atogepant

Cabergoline is a potential add-on treatment option in patients with migraine

Nitroglycerin-induced migraine targetable by different agents

Rimegepant reduces migraine symptoms through 1 year of treatment

Fremanezumab is a treatment option for paediatric patients with episodic migraine

What brain changes are associated with fremanezumab treatment success?

Preventative Therapies in Real-world Context

Low discontinuation rates with preventative galcanezumab in a real-world setting

Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders

Biofeedback training can reduce affected days in episodic migraine

Virtual reality interventions can reduce pain perception of chronic headache

Risk Factors and Long-term Management

Can predisposing factors be targeted to reduce new migraine incidence?

Active migraine comes at a high cost in Spain

Many patients, including non-responders, prefer triptans over non-headache-specific medication

Systemic Conditions and Migraine

DPP-4 is better target to lower migraine rates in patients with type 2 diabetes

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments